GlassScriptPhysician profile
Lindsey Halbrook
NPI 1437721354
$1,826.30
in general payments reported to CMS, 2019-2025
28 companies · $963 in 2025
The $963 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.57 · 2022: $152 · 2023: $256 · 2024: $436 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,593 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.42 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $240.41 | 2024-2025 | |
| Abbvie INC. | $238.07 | 2023-2025 | |
| Janssen Biotech, INC. | $222.65 | 2021-2025 | Tecvayli, Darzalex, Carvykti |
| Astellas Pharma US INC | $166.61 | 2023-2025 | Xospata, Cresemba |
| Pfizer INC. | $112.72 | 2023-2025 | |
| Legend Biotech USA INC. | $73.10 | 2022-2023 | Carvykti |
| Incyte Corporation | $72.79 | 2024-2025 | Jakafi, Niktimvo |
| Beigene USA, INC. | $68.45 | 2024-2025 | Brukinsa |
| Adaptive Biotechnologies Corporation | $67.46 | 2022-2025 | Clonoseq |
| Merck Sharp & Dohme LLC | $61.38 | 2022-2025 | Prevymis, Zerbaxa |
| Sanofi-Aventis U.S. LLC | $53.94 | 2024 | |
| Syndax Pharmaceuticals, INC. | $47.63 | 2025 | Revuforj |
| Daiichi Sankyo INC. | $43.80 | 2025 | Vanflyta |
| Novartis Pharmaceuticals Corporation | $39.79 | 2024 | |
| Genmab U.S., INC. | $37.59 | 2023-2024 | Epkinly |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $29.09 | 2022-2024 | Venclexta |
| Jazz Pharmaceuticals INC. | $28.02 | 2025 | |
| Kyowa Kirin, INC. | $26.20 | 2025 | |
| Blueprint Medicines Corporation | $23.24 | 2024 | Ayvakit |
| Celgene Corporation | $23.12 | 2022 | |
| Karyopharm Therapeutics INC. | $21.17 | 2025 | Xpovio |
| Apellis Pharmaceuticals, INC. | $21.10 | 2025 | Empaveli |
| Glaxosmithkline, LLC. | $19.17 | 2025 | Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $19.12 | 2023 | Imbruvica |
| Adc Therapeutics America, INC. | $18.00 | 2022 | |
| Lilly USA, LLC | $17.73 | 2025 | Jaypirca |
| Azurity Pharmaceuticals, INC. | $17.68 | 2025 | Danziten |
| Amgen INC. | $16.27 | 2023 | Blincyto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Halbrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.